Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 4Breast Neoplasms 3Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Fractures, Bone 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

Zoledronic Acid 4Denosumab 2saracatinib 1radium Ra 223 dichloride 1odanacatib 1Pamidronate 1Paclitaxel 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bone Diseases × radium Ra 223 dichloride × Clear all
NCT02442063 2016-11-30

Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Bayer

Phase 1 Completed
15 enrolled

Bone Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡